retatrutide triple agonist glp-1 gip glucagon phase 3 2025 is a triple-agonist (GLP-1 + + glucagon) and recent clinical trials are showing remarkable outcomes in obesity treatment. 🔬 Latest data highlights: • ~25–30% average body-weight reduction in long-term trials Dual and Triple Gut Peptide

Synthesized in the intestinal L-cells, GLP-1 is secreted in response to food intake, stimulating insulin secretion and inhibiting glucagon release [1]

Zinc : Zinc gluconate included to support immune, skin, and tissue wellness

Can I combine GLP-1 medications with other weight loss drugs

Mulberry Leaf: Mulberry leaf supports healthy glucose metabolism by slowing carbohydrate absorption and supporting insulin function

In clinical trials, Retatrutide treatment normalized liver fat in 90% of patients with NAFLD over 48 weeks, highlighting its significant impact on liver health

Whether its a brisk walk, a dance class, or yoga, find something you enjoy